Powered by: Motilal Oswal
01-01-1970 12:00 AM | Source: Accord Fintech
Torrent Pharmaceuticals rises on getting EIR for Gujarat Oral-Oncology manufacturing facility
News By Tags | #642 #572 #239 #8077

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

Torrent Pharmaceuticals is currently trading at Rs. 1848.30, up by 7.30 points or 0.40% from its previous closing of Rs. 1841.00 on the BSE.

The scrip opened at Rs. 1880.00 and has touched a high and low of Rs. 1880.00 and Rs. 1840.70 respectively. So far 10198 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1886.25 on 31-May-2023 and a 52 week low of Rs. 1361.03 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 1880.00 and Rs. 1797.35 respectively. The current market cap of the company is Rs. 62607.33 crore.

The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 21.04% and 7.71% respectively.

Torrent Pharmaceuticals has received Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat. The inspection has now been successfully closed by the USFDA. Earlier, USFDA had conducted inspection at the said manufacturing facility from March 13, 2023 to March 17, 2023.

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.